SCHOOL OF OSTEOPATHIC MEDICINE
Migraine in the Pregnant Patient," by Loretta Mueller, DO,
assistant professor, Clinical Family Medicine, was in The Female Patient (OB/GYN
ed.), Vol. 25, No. 1, January 2000.
Michael Gallagher, DO,
professor, Family Medicine and vice dean, SOM, presented "Clinical Trials in Headache"
at the 13th Annual Practicing Physician's Approach to the Difficult Headache Patient
course in Rancho Mirage, CA. Dr. Gallagher also presented "Differential Headache
and Atypical Facial Pain" at the 2000 mid-winter conference of the Maine Osteopathic
Association in Portland.
Biswas, PhD, professor,
Molecular Biology, received a four-year, $1,055.841 grant from the NIH/Institute
of General Medical Sciences to study "Mechanism of DNA-Protein Interaction in
assistant professor, Molecular Biology, received a four-year, $810,653 grant from
the NIH/National Eye Institute to study "Membrane Fusion in Retinal Rod Outer
Segments." Dr. Boesze-Battaglia, in conjunction with Richard Schimmel, PhD, associate
dean, GSBS, Stratford, also received a three-year, $147,258 grant-in-aid from
the American Heart Association Consortium to study "Cholesterol Organization:
A Determinant of Platelet Function."
Sal Caradonna, PhD, chair, Molecular Biology, received
a five-year, $1,187,117 grant from NIH-National Cancer Institute to study "Post-translational
Mechanisms in Uracil-DNA Repair." The co-investigator is Susan
Muller-Weeks, PhD, assistant professor, Molecular Biology.
Mary Crivellone, PhD, assistant professor, Molecular
Biology, received a five-year, $150,000 grant from the American Heart Association-Heritage
Affiliate to study "Chaperone-Assisted Assembly of Complex III of the Mitochondrial
FOR MIGRAINE HEADACHE SUFFERERS
recognized headache researcher R. Michael Gallagher, DO,
of UMDNJ's School of Osteopathic Medicine (SOM),
was principal investigator of a study that identified a new medication - zolmitriptan
- that appears to provide more rapid and longer pain relief for migraine headache
sufferers than the most commonly prescribed medication, sumatriptan.
randomized, double-blind study, conducted at SOM's University Headache Center
and 61 research centers around the country, involved more than 1,000 patients.
Zolmitriptan, known as ZOMIG, is produced by AstraZeneca of Wilmington, DE. The
findings were published in the February, 2000 issue of Headache: The Journal of
Head and Face Pain.
migraine patients, the most important characteristic of pain medication is that
it reduces discomfort and provides consistent relief. This study found significant
differences between the two medications in terms of how quickly they worked and
the duration of pain relief," Gallagher said.
migraine headache is a chronic medical condition affecting more than 28 million
Americans. No conclusive evidence exists as to the exact causes of migraines.
However, research suggests that the cerebral cortex of the brain is hyperexcitable,
setting off biological changes that result in a migraine.
Another recent study by the National Headache Foundation
revealed that 57 percent of migraine sufferers still rely on over-the-counter
medications exclusively. Moreover, the study found that people with migraines
are underdiagnosed and undertreated in the U.S. despite the availability of prescription
drugs known as triptans.
SOM-led study showed that patients who took a 2.5 milligram dose of zolmitriptan
at the onset of a migraine received faster and more consistent pain relief after
two hours than those who took a 50 milligram dose of sumatriptan. In addition,
pain relief was continuous for up to 24 hours for patients who used zolmitriptan.
Both medications are available only by prescription.
is a frequent speaker at international headache conferences, as well as principal
author and editor of the medical textbook, "Drug Treatment for Headaches," the
first reference dedicated to the pharmacologic treatment of headaches.
MANIPULATION FOR HEADACHE RELIEF
at UMDNJ-School of Osteopathic Medicine in Stratford
are studying whether osteopathic manipulation is a viable alternative to prescribing
pain medications for people who suffer from chronic tension headaches. Tension-type
headaches affect 90 percent of the population in the U.S., and are caused by the
tightening of muscles in the back of the neck and scalp.
there is anecdotal evidence that osteopathic manipulation can relieve pain caused
by tension headaches, there is no scientific proof," says Richard
T. Jermyn, DO, director of the University Back Pain Center and principal
investigator of the study. "The purpose of this study is to determine if manipulation
is as effective as medications. We believe that muscle tension can result from
a spinal dysfunction, and osteopathic manipulation can correct this dysfunction."
Osteopathic manipulation treatment (OMT) is a technique
used by osteopathic physicians, in which they use their hands to examine a patient's
musculoskeletal system and try to help diagnose and treat injury and illness.
Osteopathic manipulation is also commonly used to realign a patient's spine to
relieve neck pain.
There are two general classifications of tension-type
headaches: an episodic headache, which is usually triggered by environmental or
internal stress; and a chronic headache, which can last for days with varying
levels of pain. Episodic headaches usually disappear with the use of over-the-counter
analgesics, or withdrawal from the source of stress and a relatively brief period
of relaxation. Chronic headaches can be identified by some soreness of the skull,
which feels like a constricting head band or the tightening of a vise. Many of
these patients complain of early or frequent awakenings, sometimes a sign of underlying
depression. The primary drugs of choice for this type of headache are amitriptyline
or other tricyclic antidepressants.
"Traditionally, medications are used to treat tension-type
headaches. Some are effective, but often produce side effects such as nausea,
vomiting, intestinal discomfort and rebound headaches," says R.
Michael Gallagher, DO, director of the University Headache Center and
co-investigator of the study. "Chronic tension headache patients also tend to
overuse over-the-counter medications in search of the 'perfect' medication."
study, conducted jointly by the medical school's University Headache Center and
the University Back Pain Center, is looking to enroll 60 patients. The study will
cover approximately eight weeks: four weeks of monitoring medications and four
weeks of manipulation and medications.
TALK ABOUT TAKING CARE OF YOU! AN EDUCATIONAL BOOK ABOUT BODY SAFETY
Lori Stauffer, PhD, and Esther Deblinger, PhD Hope for Families, Inc.
sexual abuse affects boys and girls of all ages, religions, ethnic and socioeconomic
backgrounds. There is considerable evidence that when a child tells about sexual
abuse and has a supportive family who gets the appropriate help, the chances of
having significant and ongoing problems are greatly reduced.
four-part handbook is intended to help children ages 5 to 10 to develop the confidence
and skills to respond effectively to potentially abusive situations and be able
to tell about the experience as soon as possible. The book teaches children how
to talk about their bodies by giving them the correct names for different body
parts, explores "okay" and "not okay" touching, and explains what to do about
the "not okay" touching.
The material is presented in a gentle, step-by-step fashion so children can absorb
it slowly. Parents are encouraged to review the book before reading it with their
is an associate professor of psychiatry at UMDNJ-School of Osteopathic
Medicine (SOM). She also serves as the clinical director of the Center
for Children's Support, a multidisciplinary program of SOM that provides medical
and mental health services for children who have suffered abuse. Stauffer is the
founder and president of Hope for Families, Inc., a company that produces educational
materials and presentations regarding sexual abuse and other issues that can impact
families. She is also a part-time faculty instructor at the Center for Children's